Patient death rates after 28 days were relatively similar for those given remdesivir versus usual care.
Trials found that the anti-viral drug can reduce the recovery time of COVID-19 patients by four days.
The FDA issued emergency approval for the medicine, which may help hospitalized COVID-19 patients recover.
Coronavirus patients around the world have been rushing to join remdesivir studies that opened in hospitals in the last few weeks.